Celldex Therapeutics (CLDX) Common Equity (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Common Equity of $456.2 million for Q1 2026, down 35.1% year-over-year from $703.0 million in Q1 2025, and down 13.46% quarter-over-quarter from $527.2 million in Q4 2025.
Celldex Therapeutics (CLDX) Common Equity (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $456.2 million for Q1 2026.
- In Q1 2026, Common Equity fell 35.1% year-over-year to $456.2 million; the TTM figure through Mar 2026 stood at $456.2 million (down 35.1% YoY), while the FY2025 annual figure was $527.2 million, down 29.43% from the prior year.
- Common Equity for Q1 2026 stood at $456.2 million, down from $527.2 million in the prior quarter.
- The five-year high for Common Equity was $838.6 million in Q1 2024, with the low at $246.7 million in Q3 2023.
- The 5-year median for Common Equity is $456.2 million (2026), against an average of $518.6 million.
- The sharpest annual moves came in 2024 and 2026: Common Equity jumped 218.54% in 2024, then tumbled 35.1% in 2026.
- Celldex Therapeutics' Common Equity stood at $326.2 million in 2022, then jumped by 31.57% to $429.2 million in 2023, then soared by 74.06% to $747.0 million in 2024, then dropped by 29.43% to $527.2 million in 2025, then fell by 13.46% to $456.2 million in 2026.
- Business Quant data shows CLDX's Common Equity at $456.2 million in Q1 2026, $527.2 million in Q4 2025, and $598.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 714.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 714.56 Mn |
| Mar 31, 2026 | 456.23 Mn |
| Dec 31, 2025 | 527.17 Mn |
| Sep 30, 2025 | 598.36 Mn |
| Jun 30, 2025 | 655.41 Mn |
| Mar 31, 2025 | 702.98 Mn |
| Dec 31, 2024 | 747.01 Mn |
| Sep 30, 2024 | 785.91 Mn |
| Jun 30, 2024 | 813.66 Mn |
| Mar 31, 2024 | 838.61 Mn |
| Dec 31, 2023 | 429.17 Mn |
| Sep 30, 2023 | 246.72 Mn |
| Jun 30, 2023 | 277.54 Mn |
| Mar 31, 2023 | 302.74 Mn |
| Dec 31, 2022 | 326.20 Mn |
| Sep 30, 2022 | 345.42 Mn |
| Jun 30, 2022 | 365.09 Mn |
| Mar 31, 2022 | 398.10 Mn |
| Dec 31, 2021 | 419.48 Mn |
| Sep 30, 2021 | 436.71 Mn |